Peptide therapeutics can offer highly effective treatments, but many struggle with challenges such as stability and delivery. Jassim is developing chemically modified peptide therapeutics with naturally occurring organ-protective properties to improve their stability, selectivity, and effectiveness as a drug candidate. Initial work is focused on treating kidney damage associated with major heart surgery, but the technology has far-reaching implications for other organs and uses.

Combining expertise in drug development, manufacturing, regulatory science, and commercialization, Jassim is focused on advancing therapies from the laboratory toward real-world use.